Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)

NCT03211416 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT03211416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03211416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1/2
Overall status
Completed
Start date
December 7, 2017
Completion date
August 15, 2025
Enrollment
37 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult hepatocellular carcinoma, child-pugh class a, stage iii hepatocellular carcinoma, stage iiia hepatocellular carcinoma, stage iiib hepatocellular carcinoma, stage iiic hepatocellular carcinoma, stage iv hepatocellular carcinoma, stage iva hepatocellular carcinoma, stage ivb hepatocellular carcinoma